Treatment

New research highlights a growing shift toward more personalized and less aggressive treatment for Prostate Cancer, with a strong focus on improving patients’ quality of life. Doctors are moving away from a one-size-fits-all approach and using new data to identify which patients truly need intensive therapy and which may safely avoid certain treatments. Results from […]

New research suggests that combining the experimental drug evorpacept with the HER2-targeted therapy zanidatamab may help patients with heavily treated HER2-positive metastatic breast cancer. Evorpacept works by blocking CD47, a signal cancer cells use to avoid being destroyed by the immune system. Researchers also found that patients whose tumors had higher CD47 levels responded better

Treatment for HER2-positive metastatic breast cancer is evolving as antibody-drug conjugates (ADCs) move earlier in therapy. The long-standing first-line standard has been a taxane chemotherapy combined with trastuzumab and pertuzumab (THP), established by the CLEOPATRA trial. However, the DESTINY-Breast09 trial reported that trastuzumab deruxtecan (T-DXd) plus pertuzumab significantly improved outcomes, with progression-free survival reaching 40.7

A new clinical trial offers hope for patients with muscle-invasive bladder cancer (MIBC) who cannot tolerate or choose not to undergo standard chemotherapy. The phase 2 SURE-02 trial tested a combination of the targeted therapies Sacituzumab Govitecan (Trodelvy) and Pembrolizumab (Keytruda) as an alternative to radical bladder removal. The study included 49 patients, with a

A long-term analysis of the ESPAC4 trial shows that combining gemcitabine with capecitabine (GemCap) after surgery improves survival for patients with pancreatic cancer compared to gemcitabine alone. After nearly nine years of follow-up, patients receiving GemCap lived a median of 31.6 months, compared with 28.4 months for those on gemcitabine. Five-year survival was 32% versus

A study reports a potential new treatment strategy for nasopharyngeal carcinoma (NPC) by targeting a protein complex known as CRL4–DTL. Researchers used bioinformatics and laboratory experiments to identify DTL as a key gene that is highly expressed in NPC tumors. High levels of DTL were linked to more advanced disease and poorer patient outcomes, suggesting

A phase 2 clinical trial has reported encouraging results for zovegalisib (RLY-2608), a new targeted drug for advanced breast cancer. The study involved patients with HR-positive, HER2-negative metastatic breast cancer carrying PIK3CA mutations who had already progressed after standard treatments such as CDK4/6 inhibitors. Researchers found an overall response rate of 38.7%, while patients with

The Phase 3 RAMPART Trial studied the combination of Durvalumab and Tremelimumab in patients with kidney cancer who had undergone surgery. The treatment helped prevent cancer from returning, with three-year disease-free survival at 81% compared to 73% for patients under standard monitoring, reducing the risk of recurrence or death by 35%. However, the therapy also

Researchers reported encouraging results from the BEGONIA Trial, which tested a combination of the antibody-drug conjugate Dato-DXd and the immunotherapy Durvalumab in patients with metastatic triple-negative breast cancer (TNBC). The treatment showed high effectiveness, with nearly 80% of patients experiencing tumor shrinkage. Objective response rates were 79% in one group and 81.8% in another, and

Researchers studied a faster form of radiation therapy called ultra-hypofractionated radiotherapy for patients with advanced breast cancer. This approach delivers a higher radiation dose in fewer treatment sessions. In the study, patients received 25 Gy of radiation in only five sessions to the breast and nearby lymph nodes. Most of the 45 patients in the